Model-Driven Paediatric Cardiomyopathy Pathways - A Clinical Impact Assessment

Area of Science:

• Pediatric Cardiology
• Health Technology Assessment
• Computational Modeling

Background:

• Paediatric cardiomyopathy and heart failure pose significant clinical challenges.
• Existing treatment options require comprehensive data for effective pathway modeling.
• Accurate prognostication is crucial for managing pediatric heart conditions.

Purpose of the Study:

• To report intermediate results from a health technology assessment of a simulation model for paediatric cardiomyopathy.
• To develop and validate a detailed clinical pathway model for paediatric cardiomyopathy.
• To compare standard care with a novel clinical decision support tool using simulation.

Main Methods:

• Collected comprehensive data on paediatric cardiomyopathy, treatments, incidence, prevalence, and prognoses.
• Developed a clinical pathway model integrating disease stages, treatments, and transition probabilities.
• Employed a Markov decision process combining a three-stage Markov model and decision trees.
• Utilized a Markov Chain simulation tool for a ten-year cohort analysis.

Main Results:

• Early results show a slight increase in overall costs due to the decision support tool.
• Expected savings from improved care are anticipated.
• The model simulates transition probabilities and cost data for standard care versus the new tool.

Conclusions:

• The clinical decision support tool may incur initial cost increases.
• Intangible benefits, such as increased life years for severely ill children, are expected.
• Improved quality of life for moderately ill children is a key anticipated outcome, potentially outweighing costs.